Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs

被引：38

作者：

Saxon, AJ ^{[1
]}

McCarty, D

机构：

[1] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA

[2] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA

[3] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2005年 / 108卷 / 01期

关键词：

buprenorphine; pharmacotherapy; adoption of innovations;

D O I：

10.1016/j.pharmthera.2005.06.014

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment. (c) 2005 Published by Elsevier Inc.

引用

页码：119 / 128

页数：10

共 78 条

[21] Supporting the habit: income generation activities of frequent crack users compared with frequent users of other hard drugs [J].

Cross, JC ;

Johnson, BD ;

Davis, WR ;

Liberty, HJ .

DRUG AND ALCOHOL DEPENDENCE, 2001, 64 (02) :191-201

[22] Impact of formal continuing medical education - Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? [J].

Davis, D ;

O'Brien, MAT ;

Freemantle, N ;

Wolf, FM ;

Mazmanian, P ;

Taylor-Vaisey, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (09) :867-874

[23] Costs and benefits of treatment for cocaine addiction in DATOS [J].

Flynn, PM ;

Kristiansen, PL ;

Porto, JV ;

Hubbard, RL .

DRUG AND ALCOHOL DEPENDENCE, 1999, 57 (02) :167-174

[24] Chronic illicit drug use, health services utilization and the cost of medical care [J].

French, MT ;

McGeary, KA ;

Chitwood, DD ;

McCoy, CB .

SOCIAL SCIENCE & MEDICINE, 2000, 50 (12) :1703-1713

[25] Estimating the dollar value of health outcomes from drug-abuse interventions [J].

French, MT ;

Mauskopf, JA ;

Teague, JL ;

Roland, EJ .

MEDICAL CARE, 1996, 34 (09) :890-910

[26] Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment [J].

Fugelstad, A ;

Ågren, G ;

Romelsjö, A .

SUBSTANCE USE & MISUSE, 1998, 33 (14) :2803-2817

[27] Adoption of naltrexone to treat alcohol dependence [J].

Fuller, BE ;

Rieckmann, T ;

McCarty, D ;

Smith, KW ;

Levine, H .

JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2005, 28 (03) :273-280

[28] Reductions in acquisitive crime and drug use after treatment of addiction problems: 1-year follow-up outcomes [J].

Gossop, M ;

Marsden, J ;

Stewart, D ;

Rolfe, A .

DRUG AND ALCOHOL DEPENDENCE, 2000, 58 (1-2) :165-172

[29]

Grattagliano Ignazio, 2002, Ann Hepatol, V1, P162

[30] From best evidence to best practice: effective implementation of change in patients' care [J].

Grol, R ;

Grimshaw, J .

LANCET, 2003, 362 (9391) :1225-1230

← 1 2 3 4 5 6 7 8 →